To support developers to meet genotoxicity assessment requirements for regulatory filing in gene-edited cell and gene therapy development, the MaxCyte® SeQure platform provides a suite of on-target and off-target risk assessment assays.

These assays combine variant-aware screening with orthogonal biochemical and cell-based methods for nomination and confirmation to detect base edits, indels, structural rearrangements, and rare recombination events, delivering a comprehensive population-informed risk evaluation across therapeutic development to help you navigate the path to commercialization.